Krop Julie 4

What Happened
Julie Krop, Chief Medical Officer of DiaMedica Therapeutics (DMAC), received a grant/award of 67,500 derivative shares (transaction code A) on 2026-06-01. The reported acquisition price is $0.00, so no cash changed hands at grant; value to the insider will depend on future vesting and the stock price when shares vest. This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-01; filing date (Form 4): 2026-06-03 (appears timely; Form 4s are generally due within two business days).
• Award: 67,500 derivative shares granted at $0.00 per share (transaction type A).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote (vesting): 25% of the shares vest on the one‑year anniversary of the grant; the remaining 75% vests in twelve equal quarterly installments (i.e., a four‑year total schedule).
• No indication in this filing of a 10b5‑1 plan, cashless exercise, tax withholding, or sale tied to this grant.

Context
A $0.00 grant with a multi-year vesting schedule typically reflects equity compensation (e.g., RSUs or similar awards) intended to retain executives and align incentives with shareholders. Such grants do not represent an immediate purchase or sale and should be viewed as part of standard executive compensation rather than a near-term bullish or bearish trading signal.